More than 20 million people in the U.S. suffer neuropathic pain. At least 25% of those cases are classified as unexplained and considered cryptogenic sensory polyneuropathy (CSPN). There is no information to guide a physician’s drug choices to treat CSPN, but a researcher from the University of Missouri School of Medicine and MU Health Care led a first-of-its-kind prospective comparative effectiveness study.
The study compared four drugs with different mechanisms of action in a large group of patients with CSPN to determine which drugs are most useful for this condition. The study involved 40 sites and enrolled 402 patients with diagnosed CSPN who were 30 years or older and reported a pain score of four or greater on a 10-point scale.
Participants were prescribed one of four medications commonly used to treat CSPN: nortriptyline, a tricyclic antidepressant; duloxetine, a serotonin-norepinephrine reuptake inhibitor; pregabalin, an anti-seizure drug; or mexiletine, an anti-arrhythmic medication. Patients took the prescribed treatment for 12 weeks and were evaluated at four, eight and 12 weeks. Any participant who reported at least a 50% reduction in pain was deemed as demonstrating an efficacious result. Patients who discontinued the treatment drug because of adverse effects were also measured.
“This study went beyond whether the drug reduced pain to also focus on adverse effects,” said Richard Barohn, MD, lead researcher and executive vice chancellor for health affairs at the University of Missouri. “As the first study of its kind, we compared these four drugs in a real-life setting to provide physicians with a body of evidence to support the effective management of peripheral neuropathy and to support the need for newer and more effective drugs for neuropathic pain.”
Nortriptyline had the highest efficacious percentage (25%), and the second-lowest quit rate (38%), giving it the highest level of overall utility. Duloxetine had the second-highest efficacious rate (23%), and lowest drop-out rate (37%). Pregbalin had the lowest efficacy rate (15%) and Mexiletene had the highest quit rate (58%).
“There was no clearly superior performing drug in the study,” Barohn said. “However, of the four medications, nortriptyline and duloxetine performed better when efficacy and dropouts were both considered. Therefore, we recommend that either nortriptyline or duloxetine be considered before the other medications we tested.”
There are other nonnarcotic drugs used to treat painful peripheral neuropathy, including gabapentin, venlafaxine and other sodium channel inhibitors. Barohn said additional comparative effectiveness research studies can be performed on those drugs, so doctors can further build a library of data for the treatment of CSPN. His goal is to build effectiveness data on nearly a dozen drugs for CSPN.
The study, “Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS),” was recently published by JAMA Neurology.
As out-of-pocket costs for neurologic medications rise, people less likely to take them
Richard J. Barohn et al, Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS), JAMA Neurology (2020). DOI: 10.1001/jamaneurol.2020.2590
Study reveals most effective drugs for common type of neuropathic pain (2020, October 15)
retrieved 15 October 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- ASTRO highlights Winship study showing increased failure-free survival in prostate cancer - October 24, 2020
- विस्फोटक सामग्री संबंधी सेवाएँ ऑनलाइन प्रदान करने नवीन व्यवस्था प्रारंभ - October 24, 2020
- Repeal of Obamacare Could Leave Young Cancer Patients in the Lurch - October 24, 2020
- Apex Laboratories Pvt Ltd Multiple Openings for Freshers and Experienced in Production QC QA Departments Apply Now - October 24, 2020
- Proton therapy for lung cancer may help reduce risk of heart diseases - October 24, 2020
- 26 अक्टूबर को बैंक भी बंद रहेंगे - October 24, 2020
- AstraZeneca, J&J vaccine trials back on track in US - October 24, 2020
- प्रदेश के बिगड़े वन क्षेत्रों के पुनर्स्थापन के लिए निजी निवेशकों को दिया जाएगा जिम्मा -वनमंत्री कुंवर विजय शाह - October 24, 2020
- Early Appendicitis Symptoms, Signs, Treatment, Causes & Surgery - October 24, 2020
- Germany virus death toll passes 10,000: health institute - October 24, 2020